Literature DB >> 18758444

Structure of the Tribolium castaneum telomerase catalytic subunit TERT.

Andrew J Gillis1, Anthony P Schuller, Emmanuel Skordalakes.   

Abstract

A common hallmark of human cancers is the overexpression of telomerase, a ribonucleoprotein complex that is responsible for maintaining the length and integrity of chromosome ends. Telomere length deregulation and telomerase activation is an early, and perhaps necessary, step in cancer cell evolution. Here we present the high-resolution structure of the Tribolium castaneum catalytic subunit of telomerase, TERT. The protein consists of three highly conserved domains, organized into a ring-like structure that shares common features with retroviral reverse transcriptases, viral RNA polymerases and B-family DNA polymerases. Domain organization places motifs implicated in substrate binding and catalysis in the interior of the ring, which can accommodate seven to eight bases of double-stranded nucleic acid. Modelling of an RNA-DNA heteroduplex in the interior of this ring demonstrates a perfect fit between the protein and the nucleic acid substrate, and positions the 3'-end of the DNA primer at the active site of the enzyme, providing evidence for the formation of an active telomerase elongation complex.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758444     DOI: 10.1038/nature07283

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  130 in total

1.  In silico evaluation of TERT inhibition by anticancer drugs.

Authors:  Porika Mahendar; Kalam Sirisha; Umasankar Kulandaivelu; Prakhya Laxmi Jaya Shankar; Tippani Radhika; Abbagani Sadanandam
Journal:  J Mol Model       Date:  2012-06-06       Impact factor: 1.810

2.  Human telomerase domain interactions capture DNA for TEN domain-dependent processive elongation.

Authors:  Aaron R Robart; Kathleen Collins
Journal:  Mol Cell       Date:  2011-04-21       Impact factor: 17.970

3.  RNA/DNA hybrid binding affinity determines telomerase template-translocation efficiency.

Authors:  Xiaodong Qi; Mingyi Xie; Andrew F Brown; Christopher J Bley; Joshua D Podlevsky; Julian J-L Chen
Journal:  EMBO J       Date:  2011-10-11       Impact factor: 11.598

4.  Tetrahymena telomerase protein p65 induces conformational changes throughout telomerase RNA (TER) and rescues telomerase reverse transcriptase and TER assembly mutants.

Authors:  Andrea J Berman; Anne R Gooding; Thomas R Cech
Journal:  Mol Cell Biol       Date:  2010-08-16       Impact factor: 4.272

5.  Structurally conserved five nucleotide bulge determines the overall topology of the core domain of human telomerase RNA.

Authors:  Qi Zhang; Nak-Kyoon Kim; Robert D Peterson; Zhonghua Wang; Juli Feigon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-21       Impact factor: 11.205

6.  Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase.

Authors:  Peng Gong; Olve B Peersen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-10       Impact factor: 11.205

7.  Structure of Tetrahymena telomerase reveals previously unknown subunits, functions, and interactions.

Authors:  Jiansen Jiang; Henry Chan; Darian D Cash; Edward J Miracco; Rachel R Ogorzalek Loo; Heather E Upton; Duilio Cascio; Reid O'Brien Johnson; Kathleen Collins; Joseph A Loo; Z Hong Zhou; Juli Feigon
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

Review 8.  Telomerase Mechanism of Telomere Synthesis.

Authors:  R Alex Wu; Heather E Upton; Jacob M Vogan; Kathleen Collins
Journal:  Annu Rev Biochem       Date:  2017-01-30       Impact factor: 23.643

Review 9.  Chromosome end maintenance by telomerase.

Authors:  Jennifer L Osterhage; Katherine L Friedman
Journal:  J Biol Chem       Date:  2009-03-12       Impact factor: 5.157

10.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.